Pharming Group (NL:PHARM)
:PHARM
Total Valuation
Pharming Group has a market cap or net worth of €1.01B. The enterprise value is €1.12B.
Market Cap€1.01B
Enterprise Value€1.12B
Share Statistics
Pharming Group has 701,404,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding701,404,050
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Pharming Group’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 1.01%.
Return on Equity (ROE)0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)1.01%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee968.98K
Profits Per Employee7.34K
Employee Count404
Asset Turnover0.78
Inventory Turnover0.73
Valuation Ratios
The current PE Ratio of Pharming Group is 347.8. Pharming Group’s PEG ratio is -2.75.
PE Ratio347.8
PS Ratio2.64
PB Ratio3.72
Price to Fair Value3.72
Price to FCF20.17
Price to Operating Cash Flow21.25
PEG Ratio-2.75
Income Statement
In the last 12 months, Pharming Group had revenue of 391.47M and earned 2.97M in profits. Earnings per share was <0.01.
Revenue391.47M
Gross Profit344.11M
Operating Income20.10M
Pretax Income13.37M
Net Income2.97M
EBITDA31.77M
Earnings Per Share (EPS)<0.01
Cash Flow
In the last 12 months, operating cash flow was 51.26M and capital expenditures -760.85K, giving a free cash flow of 50.50M billion.
Operating Cash Flow51.26M
Free Cash Flow50.50M
Free Cash Flow per Share0.07
Dividends & Yields
Pharming Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.08
52-Week Price Change88.79%
50-Day Moving Average1.42
200-Day Moving Average1.27
Relative Strength Index (RSI)55.89
Average Volume (3m)19.18M
Important Dates
Pharming Group upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Pharming Group as a current ratio of 2.59, with Debt / Equity ratio of 41.79%
Current Ratio2.59
Quick Ratio2.03
Debt to Market Cap0.10
Net Debt to EBITDA-0.95
Interest Coverage Ratio1.06
Taxes
In the past 12 months, Pharming Group has paid 10.73M in taxes.
Income Tax10.73M
Effective Tax Rate0.80
Enterprise Valuation
Pharming Group EV to EBITDA ratio is 31.53, with an EV/FCF ratio of 19.57.
EV to Sales2.56
EV to EBITDA31.53
EV to Free Cash Flow19.57
EV to Operating Cash Flow19.28
Balance Sheet
Pharming Group has €179.88M in cash and marketable securities with €115.79M in debt, giving a net cash position of €64.09M billion.
Cash & Marketable Securities€179.88M
Total Debt€115.79M
Net Cash€64.09M
Net Cash Per Share€0.09
Tangible Book Value Per Share€0.20
Margins
Gross margin is 87.89%, with operating margin of 5.13%, and net profit margin of 0.76%.
Gross Margin87.89%
Operating Margin5.13%
Pretax Margin3.42%
Net Profit Margin0.76%
EBITDA Margin8.12%
EBIT Margin5.13%
Analyst Forecast
The average price target for Pharming Group is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast24.19%
EPS Growth Forecast99.16%